Drreddys Laboratories | RDY - Selling And Administration Expenses


Drreddys Laboratories reported INR26.92B in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
ANI Pharmaceuticals USD 76.66M 5.11M Sep/2025
Aurora Cannabis CAD 41.79M 3.84M Sep/2025
Bayer EUR 3.4B 140M Sep/2025
Canopy Growth CAD 29.53M 999K Sep/2025
Cipla INR 13.25B 101.8M Dec/2025
Corcept Therapeutics USD 106.97M 3.12M Sep/2025
Drreddys Laboratories INR 26.92B 3.74B Dec/2025
GlaxoSmithKline GBP 2.16B 19M Sep/2025
Hikma Pharmaceutical USD 139M 149M Jun/2025
Novartis USD 3.31B 134M Sep/2025
Pacira USD 91.8M 14.6M Sep/2025
Prestige Brands USD 28.04M 419K Sep/2025
Richter Gedeon HUF 52.3B 1.18B Sep/2025
Sun Pharmaceuticals INR 24.89B 637.6M Mar/2025
Supernus Pharmaceuticals USD 179.68M 117.46M Sep/2025
Teva Pharmaceutical Industries USD 1.12B 147M Dec/2025